zepbound tirzepatide canada Weight-loss drug approved to treat sleep apnea in Canadian residents only | Zepbound™
Description
Retrieved from Fisman, E
Tirzepatide is a dual GIP and GLP-1 receptor agonist
The focus is on a science-first methodology, ensuring your care is safe, reliable, and designed for consistency
Retatrutide has not yet been studied in a dedicated sleep apnea trial, but given its greater weight loss, the expectation is that sleep apnea improvements would be at least as significant as those seen with tirzepatide, possibly more so
.webp)
Patients should choose a timing approach that best supports their adherence and tolerability preferences
